Endocrine Abstracts

Conventional therapy for chronic hypoparathyroidism is oral calcium and active vitamin D; despite treatment, chronic hypoparathyroidism may be associated with increased risk of renal complications. Without the effect of parathyroid hormone on renal tubular reabsorption, calcium-conserving and phosphaturic effects are lost, serum calcium levels are reduced and serum phosphate levels are increased. This may lead to hypercalciuria and hyperphosphataemia, which may be associated w...

Objective: Primary aldosteronism (PA) is the first cause of endocrine hypertension accounting for about 6% of all cases of hypertension. According to international guidelines, PA screening is based on plasma aldosterone-to-renin concentration ratio (ARR) computation. Nevertheless, measurement of urine aldosterone excretion may be of interest since it integrates aldosterone secretion over 24 hours. However, available urine aldosterone immuno-assays have poor specificity.<p ...

Background: Hypercalcemia is a well-described paraneoplastic manifestation encountered in a variety of malignancies. However, it is rarely the initial feature of a neuroendocrine tumor.Herein we report a caseof metastatic pancreatic neuroendocrine tumor (NET)presenting with a refractory hypercalcemia and initially misdiagnosed as an adenocarcinoma of the pancreas.Objective: The aim of this case report is to illustratesome of thecom...

PARADIGHM™, a global, prospective, observational registry of patients with chronic hypoparathyroidism (HPT), began enrolment in 2013 to collect data on the natural history of chronic HPT (ClinicalTrials.gov NCT01922440). Since initiation, recombinant human PTH, rhPTH(1-84), has been approved in the United States and Europe as an adjunctive treatment for adult patients with HPT. The protocol for the registry (now a European Medicines Agency–designated postm...

PARADIGHM is an actively recruiting, prospective, observational registry (NCT01922440/EUPAS16927). The primary objective is to evaluate the safety and effectiveness of recombinant human parathyroid hormone, rhPTH(1-84), treatment in patients with chronic hypoparathyroidism under routine clinical care. The secondary objective is tocharacterize the clinical course of chronic hypoparathyroidism under conditions of routine clinical practice. At enrollment, registry inclusion crite...